Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427137 | 0.90 | TDP1 (0.64) | TDP1L3MBTL1LTA4HEPHX2FFAR1 | |
| SCHEMBL7635703 | 0.85 | TSHR (0.48) | L3MBTL1LTA4HNPC1RAB9ABCHE | |
| SCHEMBL3106481 | 0.84 | LTA4H (0.64) | TDP1L3MBTL1LTA4HEPHX2RAB9A | |
| SCHEMBL16594362 | 0.84 | TSHR (0.56) | TDP1L3MBTL1LTA4HNPC1RAB9A | |
| SCHEMBL4167946 | 0.84 | LTA4H (0.59) | TDP1L3MBTL1LTA4HEPHX2NPC1 | |
| SCHEMBL3120643 | 0.83 | TSHR (0.50) | L3MBTL1NPC1RAB9A | |
| SCHEMBL5677947 | 0.83 | LMNA (0.62) | L3MBTL1LTA4HNPC1RAB9ABCHE | |
| SCHEMBL903883 | 0.82 | TSHR (0.58) | L3MBTL1NPC1RAB9A | |
| SCHEMBL9478520 | 0.82 | KCNA3 (0.56) | LTA4HFFAR1BCHE | |
| SCHEMBL10713484 | 0.81 | TSHR (0.54) | TDP1L3MBTL1LTA4HNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105309-A1 | Medicinal Compounds | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-1675823-B1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | TDP1 3436/4885L3MBTL1 3752/4885LTA4H 504/4885 |
| US-20090105309-A1 | Medicinal Compounds | ADRB2, ADRB1, ADRB3 | TDP1 4766/4885L3MBTL1 4279/4885LTA4H 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.